Fulcrum Stock Crashes After Scrapping Sickle Cell Drug Over FDA Cancer Fears
Fulcrum stock dropped after canceling its sickle cell drug over cancer risk concerns; may sell company, $333M cash.
/ 352 items
#XY Event-Driven Stocks↓
Outlook Therapeutics Resubmits FDA Application for LYTENAVA – Wet AMD Treatment One Step Closer to Approval
Outlook resubmits FDA application for LYTENAVA eye injection for wet AMD. Decision expected in 60 days.
Edgewise Sells Sevasemten for Up to $2.65 Billion & Goes All-In on Heart Drugs
Edgewise sells Sevasemten to Servier for up to $2.65B and shifts focus to heart drugs for cardiomyopathy and heart failure.
Immuneering’s Pancreatic Cancer Drug Doubles Survival to 17.3 Months — Stock Falls Anyway
Immuneering's drug combo doubled pancreatic cancer survival (17.3 vs 8.5 months) and looked safe, but shares dropped.
Avenzo Goes Public: $215 Million Merger with Rallybio to Fight Cancer
Rallybio merges with Avenzo to boost cancer drug development; new AVZO company gets $215M funding and Nasdaq listing.
Cardiff Oncology Downgraded by Two Analysts After Nerviano Terminates Onvansertib License
Cardiff was downgraded by TD Cowen and H.C. Wainwright after Nerviano Medical Sciences terminated the onvansertib license agreement. Company calls termination invalid and is fighting in court.